

Carbapenem-resistant *Enterobacteriaceae* and *Candida auris*

Surveillance Report

April - June 2021

Carbapenem-resistant *Enterobacteriaceae* (CRE): April — June 2021

Carbapenemase-Producing (CP) Status of Confirmed Cases

CP-CRE	35 (66%)
Non-CP CRE	9 (17%)
CP Status Pending/Not Tested	9 (17%)
Total Confirmed CRE Cases	53

CP testing capabilities of 14 clinical laboratories in Philadelphia (as of Spring 2020)


Detection Method	n (%)
Carba NP, Modified Hodge, or other phenotypic testing only	2 (14)
PCR or other genotypic testing	3 (22)
No regular CP testing	9 (64)

CRE Counts, by Genus Species and Mechanism (n=53)

Genus Species	Total CRE n (%)	Total CP-CRE	KPC	NDM	OXA-48	IMP	VIM
<i>Klebsiella pneumoniae</i>	26 (49)	20	20
<i>Escherichia coli</i>	13 (24)	9	6	3	.	.	.
<i>Klebsiella oxytoca</i>	2 (4)	2	1	1	.	.	.
<i>Enterobacter cloacae</i>	5 (9)	1	1
Other <i>Enterobacteriaceae</i>	2 (4)	1	1
<i>Citrobacter freundii</i>	1 (2)	1	1
Other <i>Citrobacter spp.</i>	1 (2)	1	1
<i>Enterobacter aerogenes</i>	3 (6)	0	0
Total	53	35	31	4	0	0	0


CRE Cases, by Carbapenemase-Producing (CP) Status: July 2020—June 2021

202 CRE Cases
 181 (90%) Tested for CP Status
 76% CP-CRE
 24% Non-CP CRE



Candida auris Report: July 2020—June 2021

Candida auris Cases in Philadelphia by Month/Year



Candida auris is an emerging threat in the southeastern PA and Philadelphia regions. The first *C. auris* case in PA was reported in March 2020 in an individual who likely acquired the organism out of state, however, all of the cases in 2020 and 2021 thus far are part of local healthcare facility clusters. For more information, see the recent joint [PDPH and PADOH Health Alert](#) or the [C. auris webpage on the PDPH Health Information Portal](#).

Suspected or confirmed cases of *C. auris* should be reported to PDPH by calling 215-685-6748 within 24 hours. Complete the [Candida auris Report Form](#) and fax to 215-238-6947 **after reporting the case by phone**.